RVLPQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RVLPQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. RVL Pharmaceuticals's Pre-Tax Income for the three months ended in Jun. 2023 was $-24.00 Mil. RVL Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was $8.26 Mil. Therefore, RVL Pharmaceuticals's pretax margin for the quarter that ended in Jun. 2023 was -290.65%.
The historical rank and industry rank for RVL Pharmaceuticals's Pretax Margin % or its related term are showing as below:
The historical data trend for RVL Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RVL Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Pretax Margin % | Get a 7-Day Free Trial | -45.00 | -124.16 | -341.46 | -471.60 | -104.00 |
RVL Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Pretax Margin % | Get a 7-Day Free Trial | -140.02 | -143.51 | -189.70 | -130.82 | -290.65 |
For the Biotechnology subindustry, RVL Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where RVL Pharmaceuticals's Pretax Margin % falls into.
Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.
RVL Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as
Pretax Margin | = | Pre-Tax Income (A: Dec. 2022 ) | / | Revenue (A: Dec. 2022 ) |
= | -51.712 | / | 49.721 | |
= | -104.00 % |
RVL Pharmaceuticals's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as
Pretax Margin | = | Pre-Tax Income (Q: Jun. 2023 ) | / | Revenue (Q: Jun. 2023 ) |
= | -24.002 | / | 8.258 | |
= | -290.65 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RVL Pharmaceuticals (OTCPK:RVLPQ) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of RVL Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Foundation Harsaul | 10 percent owner | EDIFICIO AFRA, AVENIDA SAMUEL LEWIS Y CALLE 54, PANAMA R1 |
Altchem Ltd | 10 percent owner | KARAISKAKI 6, CITY HOUSE, LIMASSOL G4 3032 |
Alisa Lask | director | C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
David F Burgstahler | director, 10 percent owner | C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866 |
Athyrium Opportunities Associates Iv Co-invest Llc | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Athyrium Opportunities Associates Iv Lp | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Athyrium Opportunities Associates Iv Gp Llc | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Athyrium Opportunities Iv Co-invest 2 Lp | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Athyrium Opportunities Iv Acquisition 2 Lp | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Athyrium Funds Gp Holdings Llc | 10 percent owner | 505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017 |
Avista Healthcare Partners, L.p. | 10 percent owner | 65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022 |
Brian A Markison | director, officer: Chief Executive Officer | 501 FIFTH STREET, BRISTOL TN 37620 |
Sriram Venkataraman | director, 10 percent owner | C/O AVISTA CAPITAL PARTNERS, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022 |
Jeffrey Ferrell | 10 percent owner | ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FL 18, NEW YORK NY 10017 |
James Schaub | officer: EVP and COO | 400 CROSSING BOULEVARD, C/O OSMOTICA PHARMACEUTICALS PLC, BRIDGEWATER NJ 08807 |
From GuruFocus
By Marketwired • 07-05-2023
By Marketwired • 08-23-2023
By Ds*** Ds*** • 08-30-2022
By PRNewswire PRNewswire • 07-08-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By GlobeNewswire GlobeNewswire • 08-04-2022
By PRNewswire PRNewswire • 06-08-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By Stock market mentor Stock market mentor • 01-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.